In a nutshell This trial was carried out to assess the effectiveness of anlotinib (AL3818) on different subtypes of non-small cell lung cancer (NSCLC). The trial demonstrated that anlotinib improved progression-free survival (PFS) and overall survival (OS) in patients with adenocarcinoma (ACC) and tended to improve survival in...
Read More
In a nutshell The study evaluated whether exposure to checkpoint blockade therapy (CBT) can make relapsed/refractory (R/R) Hodgkin lymphoma (HL) sensitive to further treatments. The main finding was that CBT may make patients with R/R-HL responsive to further treatments. Some background While a large percentage of patients with HL can ve cured with...
Read More
In a nutshell The study evaluated outcomes of bipolar androgen therapy (BAT) in men with metastatic castration-resistant prostate cancer (mCRPC) who were continuing drugs targeting androgen receptors (AR). The authors found that BAT was clinically effective in such patients. Some background BAT refers to sequential injections with testosterone in men...
Read More
In a nutshell This study aimed to investigate cytarabine (Cytosar-U), aclarubicin (Aclacin) and G-CSF (Neupogen) as a salvage treatment for adult patients with relapsed or refractory T cell acute lymphoblastic leukemia. This study concluded that this treatment combination is safe and effective as a salvage treatment...
Read More
In a nutshell This study aimed to investigate if acalabrutinib (Calquence) was safe and effective as a treatment for patients with relapsed or refractory chronic lymphocytic leukemia. This study concluded that acalabrutinib was safe and effective in these patients. Some background Acalabrutinib is commonly...
Read More
In a nutshell This study examined if pre-treatment with immunotherapy could improve the effectiveness of following treatment for patients with hard-to-treat non-Hodgkin lymphoma (NHL). The results indicated that immunotherapies increased the effectiveness of other treatments such as chemotherapy for some patients. Some background While...
Read More
In a nutshell This study looked at abemaciclib (Verzenio), trastuzumab (Herceptin), and fulvestrant (Faslodex) for the treatment of advanced hormone-receptor-positive (HR+) and HER2 positive (HER2+) breast cancer. It found that this treatment led to better outcomes than standard-of-care chemotherapy for these patients. Some background Worldwide,...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients. Some background Bruton...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of zanubrutinib in patients with relapsed/unresponsive chronic lymphocytic leukemia and small lymphocytic lymphoma. This study concluded that zanubrutinib was well tolerated and with promising effectiveness in these patients. Some background Bruton tyrosine...
Read More
In a nutshell This study examined the safety and effectiveness of targeted therapy abemaciclib (Verzenio) for patients with relapsed or refractory mantle cell lymphoma (MCL). The results showed that abemaciclib had promising effectiveness and was relatively safe in these patients. Some background MCL is an aggressive type of lymphoma. During...
Read More
In a nutshell This study investigated the benefits of repeated cytoreductive surgery (CRS) and hyperthermic peritoneal chemotherapy (HIPEC) in patients with advanced colorectal cancer. Researchers suggested that repeated treatment improves the survival of patients with advanced colorectal cancer, without an increase in side effects. Some background...
Read More
In a nutshell This study aimed to investigate the outcomes of anti-CD19 chimeric antigen receptor T cells in patients with relapsed or refractory (unresponsive) chronic lymphocytic leukemia. This study concluded that high-dose treatment may be more effective in these patients in the long term. Some background Chimeric antigen...
Read More
